GTx Inc. (NASDAQ:GTXI) major shareholder Peak Foundation Pyramid purchased 7,716,049 shares of the company’s stock in a transaction dated Friday, October 14th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $6,249,999.69. Following the transaction, the insider now directly owns 38,249,528 shares in the company, valued at $30,982,117.68. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of GTx Inc. (NASDAQ:GTXI) traded up 0.9674% on Monday, hitting $0.9289. The stock had a trading volume of 162,071 shares. The stock has a market cap of $131.82 million, a PE ratio of 5.5958 and a beta of 2.35. GTx Inc. has a 12 month low of $0.29 and a 12 month high of $1.15. The stock has a 50 day moving average of $0.74 and a 200-day moving average of $0.66.
GTx (NASDAQ:GTXI) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. Equities research analysts anticipate that GTx Inc. will post ($0.12) EPS for the current year.
A number of brokerages have recently commented on GTXI. Jefferies Group dropped their price target on GTx from $0.75 to $0.50 and set a “hold” rating on the stock in a research report on Wednesday, August 10th. Zacks Investment Research raised GTx from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th.
A hedge fund recently raised its stake in GTx stock. BVF Inc. IL increased its position in shares of GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx comprises about 1.4% of BVF Inc. IL’s investment portfolio, making the stock its 21st largest position. BVF Inc. IL owned approximately 8.12% of GTx worth $5,756,000 as of its most recent SEC filing. 10.78% of the stock is currently owned by institutional investors and hedge funds.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.